42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01381094 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Kidney Disease

Interventions

DRUG: AKB-6548
DRUG: Placebo

Sponsor

Akebia Therapeutics